QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

MBX

QT53MBX Biosciences, Inc. Common Stock
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
43.03
+1.44+3.46%
OverviewShort InterestFilings
MBXQT53MBX Biosciences, Inc. Common Stock·NASDAQ
OverviewShort InterestFilings
43.03+3.46%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-
Insider Own13.51%
Shs Outstand47.60M
Perf Week15.52%
Market Cap1.40BForward P/E-EPS next Y-3.89Insider Trans0.30%Shs Float-Perf Month41.59%
Enterprise Value1.35BPEG19.92EPS next Q-Inst Own-Short Float-Perf Quarter51.35%
Income-62452079.00P/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y55.06%
Sales-P/B4.43EPS next Y-38.54%ROA-19.13%Short Interest-Perf YTD36.43%
Book/sh4.60P/C-EPS next 5Y-ROE-24.50%52W High45.85 -6.15%Perf Year326.04%
Cash/sh4.73P/FCF-EPS past 3/5Y-ROIC-22.54%52W Low9.43 356.31%Perf 3Y-
Dividend Est.-EV/EBITDA-15.66Sales past 3/5Y-Gross Margin0.00%Volatility9.41% 6.04%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)2.95Perf 10Y-
Dividend Ex-Date-Quick Ratio30.79Sales Y/Y TTM-Profit Margin0.00%RSI (14)72.48Recom2.50
Dividend Gr. 3/5Y-Current Ratio30.79EPS Q/Q-SMA2028.54%Beta1.70Target Price68.80
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA5029.88%Rel Volume1.20Prev Close41.59
Employees43LT Debt/Eq0.00Earnings-SMA20050.60%Avg Volume693.56KPrice43.03
IPO DateJan 14, 2000Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA0.52Volume831,968Change3.46%
Analyst Ratings
DateActionAnalystRatingTarget
May-12-26ReiteratedStifel Nicolaus$50 → $56
May-12-26ReiteratedBarclaysOverweight$66 → $70
May-11-26ReiteratedTruist Financial$50 → $70
Mar-09-26ReiteratedTruist Financial$50
Jan-27-26InitiatedBarclaysOverweight$66
Jan-16-26ReiteratedGuggenheimBuy$44 → $88
Jan-07-26ReiteratedUBS$60
Dec-19-25ReiteratedStifel Nicolaus$45 → $50
Dec-04-25InitiatedGoldman SachsSell$18
Aug-05-25InitiatedMizuhoOutperform$38
Latest News
Jun-12-26
Jun-12-2602:32PM
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide TranscriptSeekingAlpha
12:30PM
These stocks that are showing activity before the opening bell on Friday.ChartMill
10:43AM
MBX Biosciences Highlights Sustained Calcium Control In Rare DiseaseBenzinga
09:43AM
MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once-Weekly Canvuparatide - SlideshowSeekingAlpha
08:05AM
12 Health Care Stocks Moving In Friday's Pre-Market SessionBenzinga
08:02AM
Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Market SessionBenzinga
07:02AM
MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoing OLE Study Of Once-Weekly Canvuparatide In Adult Patients With Chronic HypoparathyroidismBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue
000
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A
000
Gross Profit
000
Selling, General and Administrative Excl. Other19117
Research and Development795729
Other Operating Expense00-1
Operating Income-98-68-35
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-11-6-3
Net Income Before Taxes-87-62-33
Income Taxes
000
Consolidated Net Income-87-62-33
Net Income From Continuing Operations-87-62-33
Net Income-87-62-33
EPS (Recurring)-2.38-1.85-1.02
EPS (Basic, Before Extraordinaries)-2.38-1.85-1.02
EPS (Diluted)-2.38-1.85-1.02
EBITDA-87-62-32
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
———
Gross Margin
———
Operating Margin
———
Net Margin
———
Shares Outstanding373332
Market Capitalization1,167——
Operating Lease Expense
———
Insider Trading Volume
$46.00$39.57$33.15$26.72$20.29● Close Price0.00M3.00M6.00M9.00M12.00MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Azoulay SalomonChief Medical OfficerMay 08 '26Option Exercise11.65140,0061,630,696194,540May 11 12:00 AM
Azoulay SalomonChief Medical OfficerMay 08 '26Sale38.3670,0032,685,51514,769May 11 12:00 AM
Azoulay SalomonChief Medical OfficerMay 06 '26Sale29.542316,82414,769May 08 12:00 AM
Hawryluk P. KentPresident & CEOMay 06 '26Sale29.5460717,931727,667May 08 12:00 AM
Hawryluk P. KentPresident & CEOMar 13 '26Buy28.4118,500525,663486,777Mar 16 12:00 AM
Hawryluk P. KentPresident & CEOFeb 26 '26Option Exercise16.0057,536920,576728,274Feb 27 12:00 AM
Hawryluk P. KentPresident & CEOOct 24 '25Option Exercise3.25365,7181,188,584664,256Oct 28 12:00 AM
Hawryluk P. KentPresident & CEOOct 20 '25Buy13.6420,000272,790468,277Oct 21 12:00 AM
Hoerter Steven L.DirectorOct 17 '25Buy13.2520,000264,98420,000Oct 20 12:00 AM
Heron Patrick Jdirector, 10 percent owner:Sep 26 '25Buy18.00666,66611,999,9885,219,440Sep 30 12:00 AM
Pescovitz Ora H.DirectorApr 08 '25Buy5.897,69345,31224,329Apr 10 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR